About Precia Pharma
Precia Pharma is a Healthcare company based in India founded in 2011. Precia Pharma focuses on branded prescription pharmaceuticals for lifestyle disease management, including diabetes and neuropathy treatments. The company has 1 employees. Its Indian entity Precia Pharma Private Limited reported revenue of ₹5.77 Cr. Precia Pharma offers products and services including EndoFormin and MyloNerv. Its focus areas include Pharmaceuticals, Prescription Drugs, Lifestyle Disease Management and Nutraceuticals.
Company details
Precia Pharma Private Limited is recognized as a pharmaceutical company that was established in May 2010 and began operations in October 2011, with a vision to serve as a preferred partner in the global healthcare industry. It is noted for its commitment to innovative solutions in patient care, sourcing quality products from WHO-approved plants, and developing brands for lifestyle diseases such as diabetes and neuropathy. Awards have been received by the company for its excellence, and it operates in segments like cardiology and anti-obesity, emphasizing product development driven by experienced professionals.
- Headquarters India
- Employees 1
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Social LinkedIn X Facebook
- Legal Name Precia Pharma Private Limited
- Date of Incorporation 14 May, 2010
- Jurisdiction Thane, Maharashtra, India
- Annual Revenue₹5.77 Cr
FY 2023 · -53% YoY
- Net Loss-₹3.23 Cr
FY 2023 · -56% margin
- EBITDA-₹2.51 Cr
FY 2023 · -44% margin
- Employee Count1
Associated legal entities of Precia Pharma
Precia Pharma operates through Precia Pharma Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2023) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Precia Pharma Private Limited CIN U24233MH2010PTC203201 | Active | 14 May 2010 | Thane, Maharashtra | ₹5.8 Cr | 1 | 2 | View details |
Products & Services of Precia Pharma
Precia Pharma offers a comprehensive portfolio of products and services, including EndoFormin and MyloNerv.
EndoFormin is provided as a metformin-based product utilizing Ultra High Viscosity Matrix Technology for uniform drug delivery over an extended period in a smaller tablet size.
MyloNerv is offered as a comprehensive formula containing double strength ALA 200 mg to support neuron recharging for therapeutic purposes in tablet form.
Board of directors of Precia Pharma Private Limited (Precia Pharma)
Precia Pharma Private Limited is the primary company behind Precia Pharma. The board of Precia Pharma Private Limited currently have 2 directors; the longest-serving is Sanjay Marotrao Pawar, appointed in 2010. 5 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Sanjay Marotrao Pawar DIN 02964301 | Managing Director | 14 May 2010 | 16 yrs 5 mo | Precia Pharma Private Limited |
| Anil Marotrao Pawar DIN 10239694 | Director | 14 Jul 2023 | 3 yrs 3 mo | Precia Pharma Private Limited |
Financials of Precia Pharma
Figures of Precia Pharma Private Limited, the primary company behind Precia Pharma, for FY 2023. Revenue was ₹5.77 Cr (-53% year on year). Net loss was -₹3.23 Cr (-56% margin). EBITDA was -₹2.51 Cr (-44% margin). Revenue has grown at a compounded annual rate of -26% over three years and -22% over five years.
- ₹5.77 CrRevenue · FY 2023 · -53% YoY
- -₹3.23 CrNet loss · -56% margin
- -₹2.51 CrEBITDA · -44% margin
- ₹4.31 CrPaid-up capital
- 1Employees (provident fund records)
- -26%Revenue CAGR, 3 years
- -22%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Precia Pharma Private Limited are on its company page.
Detailed financial statements for Precia Pharma
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Precia Pharma
Precia Pharma was founded in 2011.
Precia Pharma is headquartered in India.
Precia Pharma has 1 employees.
The primary company behind Precia Pharma, Precia Pharma Private Limited, reported revenue of ₹5.77 Cr for FY 2023, down 53% year on year.
Precia Pharma Private Limited is recognized as a pharmaceutical company that was established in May 2010 and began operations in October 2011, with a vision to serve as a preferred partner in the global healthcare industry. It is noted for its commitment to innovative solutions in patient care, sourcing quality products from WHO-approved plants, and developing brands for lifestyle diseases such as diabetes and neuropathy. Awards have been received by the company for its excellence, and it operates in segments like cardiology and anti-obesity, emphasizing product development driven by experienced professionals.
Precia Pharma offers EndoFormin and MyloNerv.
Precia Pharma operates through Precia Pharma Private Limited.
The legal entities of Precia Pharma currently have 2 directors, including Anil Marotrao Pawar, Sanjay Marotrao Pawar.